



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-Lipoteichoic acid [BSYX-A110 (Pagibaximab)] Standard Size Ab02032-1.4

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG1, Fc Silent™, Kappa

**Clone Number:** BSYX-A110 (Pagibaximab)

**Alternative Name(s) of Target:** LTA; Staphylococcus epidermidis lipoteichoic acid

**UniProt Accession Number of Target Protein:**

**Published Application(s):** therapeutic, ELISA

**Published Species Reactivity:** Gram Positive Bacteria

**Immunogen:** The original antibody was generated by immunizing mice with whole bacteria strain Hay Streptococcus epidermidis.

**Specificity:** This antibody targets the lipoteichoic acid (LTA) which is a major cell wall component of gram positive bacteria. LTA plays an important role in the initiation and progression of bacterial infection, inflammation, and septic shock. This antibody is also reported to bind whole bacteria for e.g. *S. epidermidis* (types I, II & III), *S. hemolyticus*, *S. hominus*, and two serotypes of *S. aureus* but not to gram negative bacteria like *E. coli*.

**Application Notes:** This antibody is also known as PMAB, A110 and Hu96-110. This humanized chimeric antibody is derived from murine antibody M110 and is reported to bind whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. It was originally developed for the prevention of staphylococcal sepsis in infants with low body weight. The serum half-life of the antibody for VLBW infants was  $20.5 \pm 6.8$  days. Pagibaximab enhanced serum opsonophagocytic activity in infants with no signs of immunogenecity of pagibaximab. All staphylococci causing sepsis were opsonizable by pagibaximab (PMID:19380597). Another study reported that three once-a-week 90 or 60 mg/kg pagibaximab infusions, in high-risk neonates, seemed safe and well tolerated (PMID: 21788224). The binding activity of the antibody to bacteria was determined using whole cell ELISA. The opsonic activity of the antibody was tested with a neutrophil mediated bacteriocidal assay. This Mab enhanced phagocytosis of both coagulase negative and positive Staphylococcus and was reported to

enhance survival in both of these types of staphylococcal infections. The results of an initial study suggests that pagibaximab at 3 and 10 mg/kg administered as a single intravenous dose in healthy adults appears to: 1) provide preliminary safety and tolerability data, 2) produce dose-related serum anti-LTA and opsonophagocytic activity levels, 3) have a half-life similar to other immunoglobulin G1 antibodies, 4) exhibit statistically significant correlation between serum anti-LTA and opsonophagocytic activity levels (PMID:19268719). This antibody was also used in combination with lysostaphin and formulated as cream and polymer delivery systems to eradicate the nasal colonization of *S. aureus* and reduce the risk of nosocomial and community acquired infections (PMID:15553221).

**Antibody First Published in:** Weisman et al. Antibody for the prevention of neonatal nosocomial staphylococcal infection: a review of the literature. *Arch Pediatr.* (2007); 14 Suppl 1:S31-4. [PMID:17939955](#)

**Note on publication:** Describes the potential use of this antibody in the prevention and treatment of neonatal nosocomial staphylococcal infections.

## Product Form

**Size:** 200 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.